Human Mesenchymal Stem Cell Transfusion for End Stage Liver Disease

Image

Human Mesenchymal Stem Cell Transfusion for End Stage Liver Disease

Journal of Cancer Research and Immuno-Oncology is an open access rapid peer reviewed journal in the field of cancer research. It is a bimonthly journal. 

In its 1st issue of 1st volume Journal of Cancer Research and Immuno-Oncology has published a case-report regarding Human Mesenchymal Stem Cell Transfusion for End Stage Liver Disease. Here we discuss a case report related to ESLD.

End-Stage Liver Disease (ESLD) is major health problems worldwide; it is the 7th leading cause of death in young and mid-age people, and the 12th leading cause of death in US, the ESLD has about 20-50% mortality rates in China. Hepatitis viruses, alcohol, diabetes, autoimmune diseases are the leading causes of decompensated liver cirrhosis which leading to high mortality, morbidity, and high healthcare costs. Because of the extreme shortage of liver donors, although liver transplantation is the only effective therapy for the end-stage liver disease, with increased waiting times and the instability of the organ resource for liver transplantation, approximately 15-20% of listed patients die by the deterioration of liver function during the waiting, and many other patients with ESLD are not candidates for liver transplantation.

In the recent decade, a growing amount of literature reporting that appropriate palliative care approach for patients who are suffering ESLD, stem cell therapy is one of the groups showing the potential to provide a valuable adjunct and alternative therapy to liver transplantation and in the management of ESLD and liver failure. Stem cell therapy might be mediated by either a direct contribution to the functional hepatocyte population with embryonic, induced pluripotent or adult stem cell or by the promotion of endogenous regenerative processes with bone marrow derived stem cells, umbilical cord derived mesenchymal stem cell as well. Previously studies have been encouraging and suggested improved liver function in end-stage liver disease, giving the possibility of time wait for transplantation. We describe a case series outcome of Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs) transfusions for decompensated liver cirrhosis as follow and reviewed the literature.

Decompensated liver cirrhosis is a severe, life-threatening situation in end-stage liver disease. Liver transplantation is the only effective therapy regarding on this. Unfortunately, the shortage of liver donors, vast of patients died during enrolled in the waiting list. There are increasing reports of using stem cell to treat advanced liver disease nowadays worldwide, and if it could be alternative therapy in persons with end-stage liver disease is not so clear. Herein we describe a case series outcome of Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) transfusions for decompensated liver cirrhosis and also reviewed the literature on stem cell therapy.

Journal of cancer research and immune-oncology announces papers for the upcoming issue. Interested can submit their manuscript through online portal

Submit manuscript at https://www.longdom.org/submissions/cancer-research-immuno-oncology.htmll or send as an e-mail attachment to the Editorial Office at cancerresearch@clinicalres.org

 

Media contact:

Maegan Smith

Managing Editor

Journal of Cancer Research and Immuno-Oncology

Mail ID: cancerresearch@clinicalres.org       

WhatsApp no: + 1-504-608-2390